An FDA-Approved Oral Minoxidil Pill Is Coming: What VDPHL01 Means for Your Beard

For 38 years, if you wanted to treat hair loss with minoxidil, you had two options: rub a liquid or foam on your head (or face), or convince a doctor to prescribe you an off-label blood pressure pill at a fraction of its original dose. Neither was ideal. The topical is messy and doesn't work for everyone. The pill carries a decades-old FDA black box warning that makes doctors nervous.

That's about to change. In April 2026, Veradermics — a dermatologist-founded biotech company — announced positive Phase 2/3 results for VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for hair loss. If approved, it would become the first FDA-approved oral treatment for pattern hair loss in nearly three decades. And for the beard growth community, the implications are significant.

What Is VDPHL01?

VDPHL01 is an extended-release formulation of minoxidil in tablet form. The key innovation isn't the drug itself — it's the delivery system. Veradermics developed a proprietary gel-matrix technology that releases minoxidil slowly and steadily over hours, rather than the rapid spike-and-crash of immediate-release oral minoxidil.

Why does this matter? The cardiac side effects that earned oral minoxidil its black box warning — rapid heart rate, fluid retention, pericardial effusion — are driven by peak plasma concentrations. When you take an immediate-release minoxidil tablet, the drug hits your bloodstream fast, spikes high, and then drops. That spike is what causes problems. VDPHL01's extended-release system is designed to avoid that spike entirely while keeping blood levels above the threshold needed for hair growth for a longer period.

The Phase 2/3 Results

Study '302' enrolled over 500 men with mild-to-moderate androgenetic alopecia in a randomized, double-blind, placebo-controlled trial. The results, announced in April 2026, showed statistically significant and clinically meaningful hair growth in the treatment groups compared to placebo. Nearly 80% of patients and investigators reported visible improvement, with measurable gains appearing as early as 2 months.

The safety profile was clean. No cardiac adverse events were reported in the trial. Side effect rates were comparable to placebo. This is a stark contrast to the safety concerns that have historically limited oral minoxidil prescribing.

Veradermics is also running a separate Phase 3 trial (Study '304') with 536 men, plus the first-ever Phase 2/3 trial of oral minoxidil for female pattern hair loss in over 500 women. Full results from these trials are expected later in 2026.

What This Means for Beard Growth

Here's where beard growers should pay attention. One of the most commonly reported "side effects" of oral minoxidil — whether prescribed for scalp hair loss or blood pressure — is increased beard growth. It's systemic, meaning the drug affects every hair follicle in the body, not just the ones you target.

Men who are currently using low-dose oral minoxidil off-label for their beards are already seeing this effect. The Liu 2025 meta-analysis documented "increased beard density" as a frequently reported observation in oral minoxidil studies. For men who don't respond to topical minoxidil (due to low sulfotransferase enzyme activity), oral minoxidil bypasses the enzyme bottleneck entirely.

If VDPHL01 gets FDA approval, it creates a new landscape:

• Legitimacy: An FDA-approved oral minoxidil product removes the "off-label blood pressure pill" stigma that makes many doctors hesitant to prescribe
• Safety: The extended-release design addresses the cardiac concerns that have been the primary barrier to wider adoption of oral minoxidil
• Access: Insurance coverage becomes possible for an FDA-approved indication, potentially reducing out-of-pocket costs
• Beard as secondary benefit: Men prescribed VDPHL01 for scalp hair loss would get beard growth as an included benefit — one pill, two results

What You Can Do Right Now

VDPHL01 isn't available yet. But the active ingredient — minoxidil — is. The options available to you today:

Topical minoxidil (OTC): 5% foam or liquid applied to the beard area twice daily. This is the studied, proven first-line approach with the least systemic risk.

Low-dose oral minoxidil (Rx): Available now through telehealth providers who prescribe it off-label. The typical starting dose for hair loss is 1.25-2.5mg daily. Requires a prescription and basic cardiovascular monitoring. This is the option that VDPHL01 aims to replace with a safer, approved formulation.

Combined approach: Some men use topical on the beard and low-dose oral for systemic coverage — getting targeted application plus whole-body follicle stimulation. Discuss dosing with your provider.

Frequently Asked Questions